---
input_text: "Impact of Gastrostomy Placement on Nutritional Status, Physical Health,
  and Parental Well-Being of Females with Rett Syndrome: A Longitudinal Study of an
  Australian Population. OBJECTIVES: To evaluate how age-related trends in nutritional
  status, physical health, and parental well-being in females with Rett syndrome may
  be related to gastrostomy placement and to examine the impact of the procedure on
  mortality. STUDY DESIGN: We included 323 females from the Australian Rett Syndrome
  Study and analyzed their demographic, genetic, and child and parental health data
  collected from over 6 waves of follow-up questionnaire between 2000 and 2011. We
  used mixed-effects models to estimate the association between repeated measures
  of outcomes and age, gastrostomy placement and their interaction and Cox proportional
  hazards regression models to estimate relative risks of mortality for individuals
  with gastrostomy. RESULTS: Nearly one-third (30.3%) of the cases underwent gastrostomy
  placement. Nutritional status based on weight, height, and body mass index (BMI)
  improved over time, and BMI was greater in individuals with gastrostomy placement
  than in those without (adjusted beta = 0.87, 95% CI 0.02-1.73). There was no association
  between gastrostomy placement and individual's physical health outcomes or parental
  physical and mental health, nor did the age trend of these outcomes vary by gastrostomy
  insertion status. Nevertheless, among those at risk of suboptimal weight, the all-cause
  mortality rate was greater in those who had gastrostomy placement compared with
  those who had not (hazard ratio 4.07, 95% CI 1.96-8.45). CONCLUSION: Gastrostomy
  placement was associated with improvement in BMI in females with Rett syndrome,
  but its long-term impact on individuals and their families is unclear."
raw_completion_output: |-
  primary_disease: Rett syndrome
  medical_actions: gastrostomy placement; nutritional status evaluation; mixed-effects models analysis; Cox proportional hazards regression models analysis
  symptoms: suboptimal weight
  chemicals: 
  action_annotation_relationships: gastrostomy placement TREATS suboptimal weight IN Rett syndrome; nutritional status evaluation MONITORS suboptimal weight IN Rett syndrome; mixed-effects models analysis ASSESSES impact OF gastrostomy placement ON nutritional status IN Rett syndrome; Cox proportional hazards regression models analysis ESTIMATES risk OF mortality AFTER gastrostomy placement IN Rett syndrome
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Cox proportional hazards regression models analysis ESTIMATES risk OF mortality AFTER gastrostomy placement IN Rett syndrome

  ===

extracted_object:
  primary_disease: MONDO:0010726
  medical_actions:
    - gastrostomy placement
    - nutritional status evaluation
    - mixed-effects models analysis
    - Cox proportional hazards regression models analysis
  symptoms:
    - suboptimal weight
  action_annotation_relationships:
    - subject: gastrostomy placement
      predicate: TREATS
      object: suboptimal weight
      qualifier: MONDO:0010726
    - subject: nutritional status evaluation
      predicate: MONITORS
      object: suboptimal weight
      qualifier: MONDO:0010726
      subject_extension: nutritional status evaluation
    - subject: <mixed-effects models analysis>
      predicate: <ASSESSES impact OF>
      object: <nutritional status>
      qualifier: <Rett syndrome>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <gastrostomy placement>
      object_extension: <nutritional status>
    - subject: <Cox proportional hazards regression models analysis>
      predicate: <ESTIMATES risk OF>
      object: <mortality>
      qualifier: <Rett syndrome>
      object_qualifier: <AFTER>
      subject_extension: <gastrostomy placement>
named_entities:
  - id: MONDO:0005647
    label: Genital warts
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0010726
    label: Rett syndrome
  - id: MONDO:0005027
    label: epilepsy
  - id: HP:0001250
    label: seizures
  - id: MAXO:0001298
    label: therapy
  - id: HP:0002186
    label: apraxia
  - id: HP:0002333
    label: motor deterioration
  - id: CHEBI:229599
    label: Trofinetide
  - id: HP:0012444
    label: Brain atrophy
  - id: CHEBI:182159
    label: Cannabidivarin (CBDV)
  - id: HP:0012531
    label: Pain
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0002540
    label: inability to walk
  - id: HP:0002300
    label: inability to speak
  - id: HP:0000787
    label: Nephrolithiasis
  - id: HP:0000016
    label: Urinary retention
  - id: MAXO:0000759
    label: HPV vaccination
  - id: MAXO:0000790
    label: Breast examinations
  - id: MAXO:0000793
    label: Pelvic examinations
  - id: HP:0100543
    label: Cognitive dysfunction
  - id: MONDO:0100039
    label: CDKL5 disorder
  - id: MAXO:0009101
    label: Early intervention
  - id: CHEBI:176843
    label: Vitamin B12
  - id: CHEBI:16347
    label: Levocarnitine
  - id: CHEBI:26708
    label: NA
  - id: CHEBI:7421
    label: N-acetyl cysteine (NAC)
  - id: CHEBI:46895
    label: LPS
  - id: CHEBI:17561
    label: L-cysteine
  - id: HP:0002360
    label: Sleep disturbances
  - id: MAXO:0000458
    label: Hydrotherapy
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0001251
    label: Ataxia
  - id: CHEBI:75883
    label: Magnetic Nanoparticle-Assisted Genome Editing (MAGE)
  - id: MONDO:0005560
    label: Brain Disorders
  - id: HP:0001298
    label: Brain Disorders
  - id: HP:0002376
    label: developmental regression
  - id: HP:0000708
    label: Behavioural problems
  - id: HP:0002607
    label: Bowel incontinence
  - id: HP:0002094
    label: Breathing difficulties
  - id: HP:0002019
    label: Constipation
  - id: HP:0011968
    label: Feeding difficulties
  - id: HP:0000020
    label: Urinary incontinence
  - id: MONDO:0001071
    label: Intellectual disability
  - id: CHEBI:3638
    label: Chloroquine
  - id: MAXO:0000943
    label: Forniceal deep brain stimulation (DBS)
  - id: HP:0002354
    label: Memory impairment
  - id: CHEBI:191875
    label: denoising source separation (DSS) algorithm
  - id: CHEBI:4806
    label: Epigallocatechin gallate (EGCG)
  - id: CHEBI:27881
    label: Resveratrol
  - id: CHEBI:46245
    label: Coenzyme Q10 (CoQ10)
  - id: CHEBI:176783
    label: Vitamin C
  - id: CHEBI:33234
    label: Vitamin E
  - id: CHEBI:15422
    label: ATP
  - id: CHEBI:13389
    label: NAD
  - id: CHEBI:15996
    label: GTP
  - id: CHEBI:16856
    label: GSH
  - id: CHEBI:17858
    label: GSSG
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: MAXO:0001394
    label: Oral administration
  - id: HP:0025464
    label: Oxidative stress
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: MONDO:0006664
    label: Autism Spectrum Disorder (ASD) and related neurogenetic syndromes
  - id: MAXO:0000506
    label: Noninvasive ventilation
  - id: MAXO:0000617
    label: Pulse oximetry
  - id: HP:0002791
    label: Hypoventilation
  - id: HP:0001249
    label: intellectual disability
  - id: HP:0000729
    label: Autistic behaviors
  - id: MONDO:0012589
    label: Pitt Hopkins syndrome (PTHS)
  - id: HP:0001257
    label: spasticity
  - id: MONDO:0000396
    label: Spastic Cerebral Palsy
  - id: HP:0002783
    label: Lower respiratory tract infection (LRTI)
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0012757
    label: Abnormal neuronal morphology
  - id: CHEBI:31236
    label: Aripiprazole
  - id: CHEBI:8871
    label: Risperidone
  - id: CHEBI:70735
    label: Lurasidone
  - id: CHEBI:33349
    label: <forniceal deep brain stimulation (DBS)>
  - id: MONDO:0004975
    label: Alzheimer's disease
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002133
    label: Status epilepticus
  - id: MAXO:0001610
    label: paired-pulse transcranial magnetic stimulation (TMS) protocols
  - id: HP:0002104
    label: apneas
  - id: MONDO:0021200
    label: Rare diseases
  - id: HP:0000739
    label: Anxiety
  - id: MONDO:0005559
    label: Neurodegeneration
  - id: CHEBI:50131
    label: 5-aza-2'-deoxycytidine (Aza)
  - id: CHEBI:230514
    label: M4
  - id: HP:0002871
    label: Central apneas
  - id: HP:0001376
    label: Decreased joint mobility
  - id: CHEBI:16865
    label: gamma-aminobutyric acid (GABA)
  - id: MONDO:0005258
    label: Autism spectrum disorder
  - id: MONDO:0008114
    label: Obsessive-compulsive disorder
  - id: MONDO:0007661
    label: Tourette syndrome
